Amphastar pharmaceuticals bolsters proprietary pipeline through exclusive licensing agreement with nanjing anji biotechnology co., ltd.

Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications rancho cucamonga, ca / access newswire / august 12, 2025 / amphastar pharmaceuticals, inc. (nasdaq:amph) ("amphastar"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today announced that it has entered into an exclusive license agreement ("agreement") with nanjing anji biotechnology co., ltd. ("anji") for the development, manufacturing, use, and commercialization of three proprietary peptides, ("licensed products"), in the united states and canada ("territory").
AMPH Ratings Summary
AMPH Quant Ranking